Humacyte, Inc. Common Stock (HUMA) is a publicly traded Healthcare sector company. As of October 28, 2026, HUMA trades at $0.45 with a market cap of $111.29M and a P/E ratio of -1.01. HUMA moved +1.05% today. Year to date, HUMA is -54.23%; over the trailing twelve months it is -73.43%. Its 52-week range spans $0.34 to $3.36. Analyst consensus is buy with an average price target of $1.75. Rallies surfaces HUMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
5 analysts cover HUMA: 0 strong buy, 3 buy, 2 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $1.75.
| Metric | Value |
|---|---|
| Price | $0.45 |
| Market Cap | $111.29M |
| P/E Ratio | -1.01 |
| EPS | $-0.51 |
| Dividend Yield | 0.00% |
| 52-Week High | $3.36 |
| 52-Week Low | $0.34 |
| Volume | 64.08K |
| Avg Volume | 0 |
| Revenue (TTM) | $2.12M |
| Net Income | $-96.73M |
| Gross Margin | -494.58% |
5 analysts cover HUMA: 0 strong buy, 3 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $1.75.